For investors on the hunt for groundbreaking technologies, stem cell therapies looked promising. But while the world waited for new treatments, Wall Street lost interest. Now, the science is accelerating, but stock prices haven't caught up.

Continue reading Stem Cell Therapies: Is Now the Time to Invest?

Stem Cell Therapies: Is Now the Time to Invest? originally appeared on DailyFinance on Tue, 13 Apr 2010 14:08:00.

Filed Under: Investing, Health Care, Genzyme Corporation , Pfizer

A government investigator found the Food and Drug Administration lax in overseeing 80% of the U.S. food supply. While food safety violations aren't always followed up and the FDA conducts fewer reviews of food manufacturing sites, it seems its work overseeing drugmakers is busier than ever.

Continue reading FDA Acts on Drugs, Warns Companies

FDA Acts on Drugs, Warns Companies originally appeared on DailyFinance on Fri, 09 Apr 2010 09:00:00.

Filed Under: Company News, Health Care, Merck

The following is a round-up of news likely to affect stock prices today:

Facet Biotech (FACT) shares soared over 67% in premarket trading after it agreed to be acquired by Abbott Laboratories (ABT) for $722 million, or $27 a share. Facet shares closed at $16.21 on Tuesday. Abbott's bid was above Biogen Idec's (BIIB) hostile offer of $17.50. Merriman downgraded FACT from buy to neutral following the...

Continue reading Stocks in the News: Facet Biotech, InterMune, American Eagle

Stocks in the News: Facet Biotech, InterMune, American Eagle originally appeared on DailyFinance on Wed, 10 Mar 2010 07:56:00.

Filed Under: Company News, Investing, J. Crew

Roche and Biogen Idec announced Monday that they were suspending the development of Ocrelizumab for the treatment of rheumatoid arthritis following serious adverse events, including deaths, of patients in studies of the drug. They are putting the program on hold and will evaluate it before proceeding any further.

Continue reading Roche, Biogen Suspend Arthritis Drug Program After Patient Deaths

Roche, Biogen Suspend Arthritis Drug Program After Patient Deaths originally appeared on DailyFinance on Mon, 08 Mar 2010 15:00:00.

Filed Under: Company News, Healthcare

Shares of AIG are on the move Monday after the insurer agreed to sell its Alico unit to MetLife for $15.5 billion. The deal is AIG's second major asset sale this month as it attempts to whittle down its bailout tab. Click inside to see what other news is influencing Wall Street today.

Continue reading Stocks in the News: AIG, Hewlett-Packard, McDonald's

Stocks in the News: AIG, Hewlett-Packard, McDonald's originally appeared on DailyFinance on Mon, 08 Mar 2010 07:43:00.

Filed Under: Company News, Investing, Hewlett-Packard, Ford Motor Co., Kraft Foods, Apple, American International Group, INC., McDonald's, Toyota, Yahoo, Astrazeneca, MetLife

The following is a round-up of news likely to affect stock prices today:

Coca-Cola (KO) reported its fourth quarter earnings climbed 55% to $1.54 billion, or 66 cents a share, on 5% higher revenue of $7.51 billion as strong volume in Latin America and other parts of the world offset a decline in North America. Results were inline with estimates. Shares rose 1.8% in premarket trading.

Continue reading Stocks in the News: Toyota, Electronic Arts, Coca-Cola

Stocks in the News: Toyota, Electronic Arts, Coca-Cola originally appeared on DailyFinance on Tue, 09 Feb 2010 07:45:00.

Filed Under: Company News, Investing, Electronic Arts, Toyota, Amgen

Biotechnology stocks pulled a huge surprise in 2009: They surged.

Few analysts expected the sector to handily outscore the rest of the market. Equally surprising was the robust performance of the young and small-cap crowd of mostly development-stage companies, which trumped their large-cap brethren. That was a switch from 2008, when the big guys outslugged the tykes, with the likes of Amgen (AMGN) and Genentech (which Roche acquired in 2009) leading the way.

Continue reading Inside Wall Street: 2010 Could Be Big for Small Biotechs

Inside Wall Street: 2010 Could Be Big for Small Biotechs originally appeared on DailyFinance on Fri, 29 Jan 2010 07:30:00.

Filed Under: Technology, Investing, Healthcare, Genzyme Corporation , Amgen

No less than three late-stage studies show that two experimental pills for multiple sclerosis -- fingolimod and cladribine -- are effective. If the drugs, developed by Novartis (NVS) and Merck Serono respectively, are approved by the FDA, they will be the first oral treatments available for the disease. Multiple sclerosis is a chronic, irreversible illness that attacks the central nervous system and is characterized by symptoms ranging from numbness to blindness and paralysis.

Continue reading Two New Multiple Sclerosis Pills Show Promise in Late-Stage Studies

Two New Multiple Sclerosis Pills Show Promise in Late-Stage Studies originally appeared on DailyFinance on Thu, 21 Jan 2010 17:00:00.

Filed Under: Company News, Healthcare, Novartis

No doubt, the loss of a Democratic Senator is not the kind of present President Obama wanted for his one-year anniversary. He would have preferred passage of his long-promised goal of health-care reform over this stunning defeat that puts any reform in jeopardy. Now that Republicans have gained filibuster power, can the Democrats still pull this one off? My colleague, Joe Lazzaro, thinks they might do it just yet. Investors, however, seem to have already started to bet against health-care reform. Already on Tuesday, the health-care and pharma sectors climbed higher, a trend that mostly continued on Wednesday.

Continue reading Health-Care Sector Appears to Rally As Reform Chances Dim

Health-Care Sector Appears to Rally As Reform Chances Dim originally appeared on DailyFinance on Wed, 20 Jan 2010 20:15:00.

Filed Under: Healthcare, Genzyme Corporation , Bristol-Myers Squibb, CIGNA Corporation, Sanofi Aventis, Merck, GlaxoSmithKline, Amgen, Eli Lilly